Part B Insider - 2005 Issue 3
Oncology: Accountability Office Can't Count, Docs Charge
Subscribe or sign in to view the full article.
Article Overview
This article covers a Government Accountability Office report on Medicare chemotherapy drug and administration fees and the response from the American Society for Clinical Oncology. It is relevant to oncology billing professionals, physician practices, and reimbursement analysts who track Medicare payment policy, drug acquisition costs, and practice expense impacts.
Why This Topic Matters
The piece highlights a payer-policy dispute that could affect oncology reimbursement planning and the interpretation of Medicare cost studies for physician practices.
What You Will Learn
- What the GAO report examined in relation to oncology drug payments
- How ASCO responded to the report's findings
- Why acquisition cost variation matters in payment analysis
- How practice expense payment changes may affect oncology compared with other specialties
Who Should Read This
- Oncology coders
- Medical billers
- Physician practice managers
- Reimbursement analysts
- Healthcare policy professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com